Jorge Posada, MD
Nephrology · Coral Gables, FLNPI 1225099195
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Astrazeneca UK Limited at 43.4% of the total.
Across 30 payments — averaging $91.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$1K
- UCB SA$714
- Novo Nordisk AS$400
- AstraZeneca$149
- GSK$119
- Amgen$65
- plus $100 from 4 others
Across 1,077 payments — averaging $2331.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$667K
- CSL Behring$428K
- GSK$359K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$276K
- Boehringer Ingelheim$200K
- UCB SA$200K
- plus $381K from 15 others
What the payments were for
- Travel & lodging$1,52856%
- Food & beverage$1,17843%
- Education$271%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 7 | $1,186 |
| UCB SA | 7 | $714 |
| Novo Nordisk AS | 1 | $400 |
| AstraZeneca | 4 | $149 |
| GSK | 5 | $119 |
| Amgen | 2 | $65 |
| Integra Lifesciences Corporation | 1 | $35 |
| Vifor Pharma, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
How this compares
$2,733 in reported general payments places this provider in the 65th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 129 | $82,532 |
| VeltassaPatiromer Calcium Sorbitex | 56 | $46,043 |
| ProcritEpoetin Alfa | 28 | $31,468 |
| EpogenEpoetin Alfa | 23 | $26,860 |
| Sevelamer Carbonate | 39 | $16,918 |
| RetacritEpoetin Alfa-Epbx | 27 | $12,417 |
| Bumetanide | 296 | $9,470 |
| Cinacalcet Hcl | 25 | $7,476 |
| Febuxostat | 115 | $7,192 |
| Hydralazine Hcl | 270 | $3,089 |
| Calcium Acetate | 13 | $686 |
| Calcitriol | 46 | $506 |
| Carvedilol | 78 | $481 |
| Nifedipine ErNifedipine | 27 | $422 |
| Furosemide | 99 | $404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEpogen | $65 | $26,86023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 756 nephrology providers in Florida.
Other nephrology in Coral Gables
- Luis Garcia-MayolCoral Gables$77K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.